Risk factors for repeat use of pulmonary surfactant in the treatment of respiratory distress syndrome in the term and near-term neonate
10.3969/j.issn.1673-6710.2016.02.008
- VernacularTitle:足月儿和近足月儿呼吸窘迫综合征需重复应用肺表面活性物质高危因素分析
- Author:
Jing YU
;
Huaping ZHU
;
Ning LI
;
Xi CHEN
;
Shiwen. XIA
- Publication Type:Journal Article
- Keywords:
Pulmonary surfactant;
Respiratory distress syndrome;
newborn;
Risk factors
- From:Chinese Journal of Neonatology
2016;31(2):115-119
- CountryChina
- Language:Chinese
-
Abstract:
Objective To identify risk factors associated with repeat use of pulmonary surfactant ( PS) in the treatment of respiratory distress syndrome ( RDS ) in the term and near-term neonate. Methods There were 130term and near-term new borns with RDS who were treated with pulmonary surfactant were enrolled. These infants were categorized into two groups: single-dose group (85 cases) and repeat-dose group (45 cases). The differences in basic information were compared between the two groups, and logistic regression analysis was used to identify the risk factors for repeat use of pulmonary surfactant.Results TherepeatutilizationrateofPSwas34.6℅.The incidence of asphyxia,maternal gestational hypertension, X-ray RDS grade 3-4, the age of first dose PS,respiratory support time in the repeat-dose group was significantly higher than in the single-dose group (P<0. 05). PaO2/FiO2 and the cure rate in the repeat-dose group were significantly lower than in single-dose group ( P<0. 05 ) . The incidence of sepsis, pulmonary hemorrhage, shock and patent ductus arteriosus ( PDA) in the repeat-dose group was significantly higher than in the single-dose group ( P<0. 05). Further logistic regression analysis showed that birth asphyxia ( OR=5. 674 , 95℅CI 1. 378 -23. 354 , the age of first dose of PS (OR=1.092, 95℅CI 1.002 -1.191)and PDA(OR =23.499, 95℅CI 2.348 -235.152)were the independent risk factors for repeat use of pulmonary surfactant.Conclusions Birth asphyxia,the age of first dose PS and PDA are the risk factors for repeat use of pulmonary surfactant in the treatment of RDS in the term and near -term neonate.
